Pizza Hut announces plans to slash 29 sites, 450 jobs
Amryt Pharma shares spike 51% with treatment passing rare skin disease trial
The EASE trial
The EASE trial is noted to be the largest trial conducted that focuses on patients with EB. It was performed across 58 sites in 28 countries, with 223 patients enrolled – including 156 pediatric patients.In a double-blind test lasting 45 days, the efficacy of FILSUVEZ was measured versus a control gel. The company stated that within this period, its treatment achieved statistical significance, which represents the first ever successful phase three top line readout in EB. It is also the fourth time that the treatment has illustrated its capacity to accelerate wound-healing in a phase three trial.
Going forwards, the company will evaluate data from the trial and present its results at an upcoming scientific symposium. Amryt Pharma stated that it intends to complete the submission of its rolling New Drug Application to the US Food and Drug Association and request a priority review for FILSUVEZ.
Amryt Pharma reaction
Commenting on the news, company CEO Joe Wiley stated:“This positive outcome of the Phase 3 EASE trial marks another significant milestone for Amryt as we seek approval for FILSUVEZ ® and represents a potentially important advancement for patients and families living with this rare and distressing disorder. If approved, we intend to leverage our existing global infrastructure to commercialize FILSUVEZ.”
“We are proud to present these positive and encouraging results, demonstrating that FILSUVEZ could make an important difference to the lives of patients. We would like to extend our gratitude to all of the patients, their families, carers and physicians for their participation in the EASE trial and we look forward to working with regulatory authorities to make FILSUVEZ available as the first approved therapeutic treatment for EB patients. All of the team at Amryt are very excited by today’s news and the impact this may have in our efforts to help patients with this very distressing condition.”
Investor notes
Following the announcement, Amryt Pharma shares rallied by 51.25% or 82.00p, to 242.00p per share 09/09/20 12:00 GMT. This price is far-and-away a new record for the company’s shares, and far ahead of its year-to-date nadir of 90.00p a share. The company’s p/e ratio is -1.80, earnings per share currently stand at -86.00p.Pound Sterling hits six-week low as it continues fall against Euro and Dollar
“As sterling nervously awaits the unveiling of Boris Johnson’s international law-breaking UK Internal Market Bill, the FTSE continued to celebrate the currency’s bout of Brexititis – a long-dormant condition that has recently seen a serious flare-up.”
“Tuesday was a rough one for the pound – against the dollar it was down 1.55%, with a 1.14% decline against the euro. Further losses on Wednesday – 0.3% and 0.2% against its respective peers – leave sterling at its worst price for 6-weeks, erasing all of the spirited growth it managed over a Brexit-ignorant August.”
There was perhaps a bright side to this dip, when we consider that correspondingly, the FTSE continued its Monday rise with a Wednesday morning rally. Having been the least-affected by the Labor Day hangover on Tuesday, the index rallied 0.89% or 53 points on Wednesday, taking it to just shy of the 6,000 mark. This small positive was somewhat overshadowed, however, as the FTSE was outdone by the DAX rallying 1.03% and the CAC not lagging far behind with a 0.83% rise. Ultimately, the continued decline of the Pound may have spurred the FTSE, but on balance this trade-off isn’t worth it.Uber pledges to go green – but is it enough?
Thomas Cook: Will the group make a successful comeback?
Iceland to hire 3,000 as business booms
i-Nexus Global shares jump 67% on contract success and reduced costs
Third and finally, the company boasted that it had successfully re-energised its sales pipeline. It said that it had successfully rebuilt its sales opportunities to pre-pandemic levels, and its pipeline now includes live opportunities with an annual recurring revenue value of £1.8 million.
i-Nexus Global cash outlook
Speaking on the company’s strategy and its financial position in the coming months, the Group’s statement read: “At the time of the Interim results update, the Company announced that the Board had resolved to review strategic options to introduce fresh capital to the business, in light of the difficult and uncertain trading environment caused by COVID-19. The Company has agreed with HMRC a deferral and repayment plan in respect of PAYE and National Insurance payments amounting to approximately £430K but has otherwise thus far been unable to secure access to additional funding.” “Based on the Company’s latest cash flow projections, the Directors anticipate that the Company is likely to experience a modest cash shortfall by the end of the calendar year, but should return to a positive cash balance from February 2021 onwards, in line with i-Nexus’ regular seasonal cashflow profile. As a result, the Board is, as a key priority, scaling up its efforts to source new financing facilities with immediate effect.”Investor notes
Following the update, the i-Nexus Global share price rally somewhat calmed down, still up 44.78% or 1.50p, to 4.85p per share 08/09/20 13:00 GMT. While this level is ahead of its year-to-date nadir of 3.25p seen in May, it is far behind where it started the year, with the price of 16.50p per share through January. The company’s p/e ratio is currently -0.26.Fevertree shares dip as sunken profits leave a bitter taste
Fevertree response
Commenting on what he described as the company’s ‘resilient’ first half performance, CEO Tim Warrillow stated:“Our performance in the Off-Trade over the first half of the year has been very encouraging with sales across our regions exceeding our expectations. People’s interest and excitement about mixing drinks at home has really taken hold over the lockdown period, attracting more households to the Fever-Tree brand than ever before. Consequently, we have increased our penetration in the UK, consolidated our number one position, and driven value share gains in the US, Europe, and as far afield as Canada and Australia. Despite the On-Trade closure for a large proportion of the first half of the year, we have continued to support our On-Trade partners across our regions and are well-placed to benefit from the return of this important channel.”
“We have had an encouraging start to the second half of the year and, while we certainly aren’t immune to the ongoing challenges of COVID-19, our performance and our investments so far this year, coupled with the growing interest in long mixed drinks, gives me confidence that we will exit the crisis in an even stronger position than we entered it.”
Investor notes
Having dropped by more than 5% after the first bell, Fevertree Drinks shares are now down 1.46% or 31.00p, to 2,089.00p a share 08/09/20 12:30 GMT. This price is short of its year-to-date high of 2,418.00p seen in July, but well ahead of its year-to-date nadir of 892.00p seen in mid-March. The Group’s p/e ratio is 40.75, its dividend yield currently stands at 0.73%.Almonty Industries Virtual Investor Presentation
Download Presentation Slides
Almonty Industries is a Tungsten-focused miner specialising in unlocking value in global Tungsten operations and is currently developing the world’s largest Tungsten mine outside of China. With applications ranging from semi conductors to space rockets, Tungsten is classed as a critical raw material by the EU due to potential supply risks and the high economic importance of the metal.- Classic pattern of mining stocks
- Almonty’s portfolio of Tungsten operations
- Almonty’s high potential in the global Tungsten market
- Exploration of other critical raw materials
Experian shares continue rally with improved second quarter expectations
Instead, what transpired was stronger than anticipated trading during July and August, which has prompted the company to offer more optimistic predictions of its Q2 results.
Experian now expects its organic revenue to grow between 3% and 5% during the quarter. It believes that its interests in the US mortgage sector will contribute as much as three percentage points to revenue growth, while it stated that the ‘strength in the services’ it provides to consumers and the ‘naturally resilient qualities’ of parts of its portfolio will also be aiding factors.It added that due to continued investments in innovation and expanding its profit range, it now anticipates a rise in organic costs between 2% and 3% during the first half of FY21.
Experian finished its update by stating that its final set of results for the period will be published on Tuesday the 17th of November 2020.
Following the update, the company’s shares now sit 2.00% or 56.00p up on where they started, up to 2,855.00p per share 08/09/20 12:00 GMT. Though its rally somewhat tapered off during Tuesday morning trading, its share price trajectory has been largely in the green since March, and largely avoided the big slump most company’s shares saw in July.
Its current price level is ahead of its 12-month consensus target price, which stands at 2,820.03p a share, but it is also shy of its year-to-date high, where it hit 2,914.00p in June. Its current level represents an 8.51% growth on its price on the same date last year.
The company’s p/e ratio stands at 35.76, its dividend yield is 1.30%.